###begin article-title 0
Levels of gastrin-releasing peptide and substance P in synovial fluid and serum correlate with levels of cytokines in rheumatoid arthritis
###end article-title 0
###begin p 1
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is cited.
###end p 1
###begin p 2
###xml 572 580 <span type="species:ncbi:9606">patients</span>
###xml 707 715 <span type="species:ncbi:9606">patients</span>
It is well known that cytokines are highly involved in the disease process of rheumatoid arthritis (RA). Recently, targeting of neuropeptides has been suggested to have potential therapeutic effects in RA. The aim of this study was to investigate possible interrelations between five neuropeptides (bombesin/gastrin-releasing peptide (BN/GRP), substance P (SP), vasoactive intestinal peptide, calcitonin-gene-related peptide, and neuropeptide Y) and the three cytokines tumour necrosis factor (TNF)-alpha, IL-6, and monocyte chemoattractant protein-1 in synovial fluid of patients with RA. We also investigated possible interrelations between these neuropeptides and soluble TNF receptor 1 in serum from RA patients. Synovial fluid and sera were collected and assayed with ELISA or RIA. The most interesting findings were correlations between BN/GRP and SP and the cytokines. Thus, in synovial fluid, the concentrations of BN/GRP and SP grouped together with IL-6, and SP also grouped together with TNF-alpha and monocyte chemoattractant protein-1. BN/GRP and SP concentrations in synovial fluid also grouped together with the erythrocyte sedimentation rate. In the sera, BN/GRP concentrations and soluble TNF receptor 1 concentrations were correlated. These results are of interest because blocking of SP effects has long been discussed in relation to RA treatment and because BN/GRP is known to have trophic and growth-promoting effects and to play a role in inflammation and wound healing. Furthermore, the observations strengthen a suggestion that combination treatment with agents interfering with neuropeptides and cytokines would be efficacious in the treatment of RA. In conclusion, BN/GRP and SP are involved together with cytokines in the neuroimmunomodulation that occurs in the arthritic joint.
###end p 2
###begin title 3
Introduction
###end title 3
###begin p 4
###xml 88 89 88 89 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B2">2</xref>
###xml 197 198 197 198 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B3">3</xref>
###xml 276 277 276 277 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B4">4</xref>
###xml 278 279 278 279 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B5">5</xref>
###xml 522 523 522 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 597 599 597 599 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 644 645 644 645 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 731 732 731 732 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 721 729 <span type="species:ncbi:9606">patients</span>
It has long been known that neuropeptides are secreted locally during immune responses [1], and that they are involved in vasodilation and plasma extravasation, that is, neurogenic inflammation [2,3]. It is furthermore known that inflammatory cells can produce neuropeptides [4,5]. The neuropeptide substance P (SP) has been extensively examined in normal joints and in rheumatoid arthritis (RA) during the past two decades. SP has known proinflammatory properties, enhancing the proliferation of rheumatoid synoviocytes [6] and inducing the release of the proinflammatory mediator prostaglandin E2 and destructive enzymes such as collagenase [6]. An increased level of SP has been observed in the synovial fluid from RA patients [7-11].
###end p 4
###begin p 5
###xml 57 59 57 59 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 169 185 169 185 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Bombina bombina </italic>
###xml 186 188 186 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B13">13</xref>
###xml 357 359 357 359 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 360 362 360 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 499 501 499 501 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 706 708 706 708 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 709 711 709 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 755 757 755 757 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 758 760 758 760 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 837 839 837 839 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 940 942 936 938 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
###xml 943 945 939 941 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 963 965 959 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B21">21</xref>
###xml 1033 1035 1029 1031 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 169 184 <span type="species:ncbi:8345">Bombina bombina</span>
###xml 688 696 <span type="species:ncbi:9606">patients</span>
###xml 1011 1017 <span type="species:ncbi:10090">murine</span>
Another neuropeptide is gastrin-releasing peptide (GRP) [12], the mammalian homologue of bombesin (BN), a tetradecapeptide originally isolated from the skin of the frog Bombina bombina [13]. BN/GRP-like peptides affect several systems in mammals, such as satiety, thermal regulation, nociception, and the activation of the sympatho-adrenomedullary outflow [14,15]. We have recently shown that BN/GRP-like peptides are present in joint fluid in arthritis and that they are increased in amount in RA [11]. Several other neuropeptides, such as vasoactive intestinal peptide (VIP), calcitonin-gene-related peptide (CGRP), and neuropeptide Y (NPY), have also been found in synovial fluid from patients with RA [10,16]. VIP is a potent anti-inflammatory agent [17,18]. It therefore has a beneficial effect in collagen-induced arthritis (CIA) [17], inhibits the production of proinflammatory factors, including tumour necrosis factor (TNF)-alpha [19,20] and chemokines [21], and inhibits IL-2 production in stimulated murine T lymphocytes [22].
###end p 5
###begin p 6
###xml 87 89 83 85 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 90 92 86 88 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
###xml 217 219 213 215 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 220 222 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 375 377 367 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 378 380 370 372 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 550 552 542 544 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 553 555 545 547 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 633 635 621 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 727 729 715 717 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B32">32</xref>
###xml 845 847 833 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 970 972 958 960 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 973 975 961 963 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 1173 1175 1161 1163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 1176 1178 1164 1166 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B38">38</xref>
###xml 163 171 <span type="species:ncbi:9606">patients</span>
###xml 298 306 <span type="species:ncbi:9606">patients</span>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
###xml 835 843 <span type="species:ncbi:9606">patients</span>
###xml 1163 1171 <span type="species:ncbi:9606">patients</span>
The proinflammatory cytokine TNF-alpha plays a central role in the pathogenesis of RA [23,24]. Increased concentrations of this cytokine in synovial fluid from RA patients have been reported in several studies (e.g. [25-27]). It has also been shown that TNF-alpha is expressed locally in joints of patients with RA and in inflamed joints in experimentally induced arthritis [28,29]. Increased concentrations of soluble TNF receptors (sTNFRs) p55 (sTNFR1) and p75 (sTNFR2) have been found in peripheral blood and synovial fluid from patients with RA [30,31]. These receptors can bind TNF-alpha and counteract its deleterious effects [30]. Serum concentrations of the two receptors have been correlated with RA disease activity [32]. The proinflammatory cytokine IL-6 is also found in elevated concentrations in the synovial fluid of RA patients [33]. The chemokine monocyte chemoattractant protein (MCP)-1 is a cytokine that attracts monocytes to a site of inflammation [34,35]. This chemokine has been suggested to be an important factor for the recruitment of leukocytes to the joints in RA and is also found in elevated concentrations in synovial fluid from RA patients [36-38].
###end p 6
###begin p 7
###xml 71 73 71 73 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 74 76 74 76 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 226 228 226 228 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B42">42</xref>
###xml 477 479 477 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B43">43</xref>
###xml 581 583 577 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 670 679 666 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 680 682 676 678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
###xml 459 467 <span type="species:ncbi:9606">patients</span>
###xml 829 837 <span type="species:ncbi:9606">patients</span>
Interactions between neuropeptides and cytokines are well known (e.g. [39-41]), and it has been suggested that regulatory neuroimmune pathways in the joints are important mechanisms modulating the expression of the arthritis [42]. However, there is limited information on the relations between neuropeptides and cytokines in the synovial fluid and serum from patients with RA. What is known is that SP and IL-6 concentrations correlate in synovial fluid from patients with RA [43]. Furthermore, the effect of SP on IL-1, IL-6, and TNF-alpha production in RA was recently examined [44]. CGRP has been found to reduce the production of IL-6 and MMP-2 in RA synovial cells in vitro [18]. To the best of our knowledge, there is no information at all on the occurrence of a possible relation between BN/GRP and cytokines in arthritic patients.
###end p 7
###begin p 8
###xml 399 401 395 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 545 547 541 543 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B46">46</xref>
###xml 548 550 544 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B49">49</xref>
###xml 761 763 757 759 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 802 811 798 807 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 953 955 949 951 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 956 958 952 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 823 828 <span type="species:ncbi:9606">human</span>
###xml 1190 1198 <span type="species:ncbi:9606">patients</span>
The lack of information on relations between neuropeptides and cytokines in RA hampers the understanding of whether neuropeptide-modifying agents, in addition to cytokine antagonists such as TNF-alpha blockers, might be useful in the treatment of RA. New information has led to suggestions that treatments interfering with neuropeptides should be tested in combination with pre-existing treatments [45]. A number of neuropeptide receptor agonists and antagonists produced during recent years have been found to have effects in other situations [46-49]. Actually, using an animal model of RA, collagen-induced arthritis, it was shown that VIP affected the Th1/Th2 balance by inhibiting the synthesis of Th1 cytokines and inducing the synthesis of Th2 cytokines [17]. Also, the results of recent studies in vitro on cells of human origin have suggested that modulation of the effects of neuropeptides may be a new strategy for the treatment of arthritis [50,51]. In the present study, we therefore aimed to investigate the relation between the concentrations of three cytokines (TNFalpha, IL-6, and MCP-1) and several neuropeptides (BN/GRP, SP, NPY, VIP, and CGRP) in the synovial fluid from patients with RA, stratified for early and long-standing disease. We also studied the concentrations of sTNFR1 in relation to these neuropeptides in serum. We found that BN/GRP and SP showed correlations with the proinflammatory cytokines in the group with long-standing RA.
###end p 8
###begin title 9
Materials and methods
###end title 9
###begin title 10
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
Patients and material
###end title 10
###begin p 11
###xml 129 131 129 131 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B52">52</xref>
###xml 333 335 333 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 383 385 383 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 24 32 <span type="species:ncbi:9606">patients</span>
###xml 37 42 <span type="species:ncbi:9606">women</span>
###xml 50 53 <span type="species:ncbi:9606">men</span>
###xml 213 221 <span type="species:ncbi:9606">patients</span>
###xml 289 297 <span type="species:ncbi:9606">Patients</span>
###xml 679 687 <span type="species:ncbi:9606">patients</span>
###xml 750 758 <span type="species:ncbi:9606">patients</span>
###xml 800 808 <span type="species:ncbi:9606">patients</span>
Thirty-five consecutive patients (25 women and 10 men) with RA according to the criteria of the American Rheumatism Association [52], having active inflammation of the knee joints, were included in the study. The patients were divided into two groups, depending on their disease duration. Patients were defined as having 'early RA' (n = 7; mean age, 51 years) or 'long-standing RA' (n = 23 to 28; mean age, 59 years). Median time when sampling of blood and synovial fluid for the early RA group was 8.0 months from onset of symptoms (interquartile range = 5.6 months); the median duration from onset of symptoms until diagnosis was 6.0 months. The early RA group were thus those patients who had had RA for less than approximately 12 months, and the patients in the long-standing RA group were those patients whose disease had lasted for more than a year.
###end p 11
###begin p 12
###xml 77 79 77 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B53">53</xref>
###xml 330 332 324 326 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 363 365 357 359 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 262 270 <span type="species:ncbi:9606">patients</span>
###xml 306 314 <span type="species:ncbi:9606">patients</span>
###xml 498 506 <span type="species:ncbi:9606">patients</span>
The synovial fluid was aspirated according to the method of Dixon and Emery [53]. The aspirates were centrifuged, and the leukocytes were removed. The samples were frozen and stored at -80degreesC until assay. Blood samples were also collected concurrently from patients whose synovial fluid was examined: patients with early RA (n = 4) or with long-standing RA (n = 22). The sera were frozen and stored at -80degreesC until assay. The erythrocyte sedimentation rate (ESR) was measured for all the patients.
###end p 12
###begin p 13
###xml 16 18 16 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 39 41 39 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 205 213 <span type="species:ncbi:9606">patients</span>
Synovial fluid (n = 2 to10) and serum (n = 2 to 11) was also obtained from healthy controls (mean age, 39 years). The samples were collected, frozen, and stored in the same way as the material from the RA patients.
###end p 13
###begin p 14
The study protocol was approved by the Ethical Committee at the Faculty of Medicine, Umea University, and the experiments were conducted according to the principles expressed in the Declaration of Helsinki.
###end p 14
###begin title 15
Enzyme-linked immunosorbent assay/enzyme immunoassay
###end title 15
###begin p 16
###xml 69 74 <span type="species:ncbi:9606">Human</span>
###xml 315 320 <span type="species:ncbi:9606">Human</span>
###xml 509 514 <span type="species:ncbi:9606">Human</span>
The concentration of TNF-alpha in joint fluid was determined using a Human ELISA TNFalpha kit (Pierce-Endogen, Rockford, IL, USA) in accordance with the instructions from the manufacturer. The detection limit in this particular assay was cited as 2 pg/ml. The receptor level of sTNFR1 in serum was measured using a Human Quantikine sTNF R1 kit (R&D Systems, Wiesbaden-Nordenstadt, Germany). The minimum detectable level for this assay was 0.77 pg/ml. The concentrations of MCP-1 and IL-6 were determined with Human ELISA kits (Pierce-Endogen). The minimum detectable concentrations for these assays were <10 pg/ml and <1 pg/ml, respectively. The concentrations of the neuropeptides BN/GRP and SP (in serum) and of the neuropeptides CGRP, NPY, and VIP (in joint fluid and serum) were measured using Enzyme Immunoassay kits (Phoenix Pharmaceuticals, Belmont, CA, USA) in accordance with the supplier's assay instructions. The detection limits for the neuropeptides were as follows: BN/GRP, 300 pg/ml; CGRP, 230 pg/ml; NPY, 130 pg/ml; SP, 90 pg/ml; and VIP, 80 pg/ml.
###end p 16
###begin title 17
Radio-immunoassay
###end title 17
###begin p 18
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 247 250 247 250 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
###xml 450 453 450 453 <sup xmlns:xlink="http://www.w3.org/1999/xlink">125</sup>
For determining concentrations of BN/GRP and SP in joint fluid, RIAs were performed. These conform to the analyses described and presented in a previous study [11]. The concentrations of BN/GRP-like material in joint fluid were determined using a 125I-RIA kit (Peninsula Laboratories Inc, San Carlos, CA, USA) in accordance with the manufacturer's instructions. The detection limit in this particular assay was cited as 10 pg/ml. For the SP assay, a 125I-RIA kit (Eurodiagnostica, Malmo, Sweden) was employed. The sensitivity of the assay was 2.5 pg/ml.
###end p 18
###begin title 19
Statistics
###end title 19
###begin p 20
###xml 182 184 182 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">U </italic>
###xml 267 269 267 269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Differences between the continuous data for concentrations of the investigated substances in the two subject groups (early RA, long-standing RA) were analysed using the Mann-Whitney U test. Correlation analyses were performed with the Spearman rank correlation test. P values <0.05 were considered significant. Because the amounts of synovial fluid and serum from healthy controls varied, no statistical analysis was performed in this case.
###end p 20
###begin p 21
Factor analysis, that is, explorative data analysis, was also performed to find patterns among the measured variables. In this case, because of the number of samples available, the pattern for long-standing RA was evaluated. Factor loadings >0.3 were considered. The factor analyses were performed by SPSS with Varimax, with Kaiser normalisation as a rotation method. For the statistical calculations, values below the detection limit were set to 50% of the detection limit and values beyond the highest standard point were set to the highest linearly detectable concentration.
###end p 21
###begin title 22
Results
###end title 22
###begin title 23
Cytokines in synovial fluid
###end title 23
###begin p 24
###xml 126 127 122 123 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 444 445 440 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 544 546 540 542 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 560 562 556 558 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1a</xref>
###xml 641 642 637 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 770 771 766 767 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
###xml 374 382 <span type="species:ncbi:9606">patients</span>
###xml 451 459 <span type="species:ncbi:9606">patients</span>
###xml 620 628 <span type="species:ncbi:9606">patients</span>
###xml 742 750 <span type="species:ncbi:9606">patients</span>
Concentrations of immunoreactive TNF-alpha in synovial fluid were detected in most of the patients (approximately 70%). Table 1 shows medians and interquartile ranges of the concentrations found. No significant differences were found between the two disease groups (Mann-Whitney test). The concentrations of immunoreactive IL-6 in synovial fluid were detected in 95% of the patients with RA. Medians and interquartile ranges are shown in Table 1. The patients with early RA had significantly higher concentrations of IL-6 than the other group (P < 0.05) (Fig. 1a). The chemoattractant cytokine MCP-1 was detected in all patients, (see Table 1). No significant differences were found between the two groups for MCP-1. Values found for control patients are shown in Table 1.
###end p 24
###begin title 25
Neuropeptides in synovial fluid
###end title 25
###begin p 26
###xml 117 118 117 118 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 264 266 264 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 280 282 280 282 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b</xref>
###xml 383 385 383 385 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F1">1b,c</xref>
###xml 464 465 464 465 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 101 109 <span type="species:ncbi:9606">patients</span>
###xml 184 192 <span type="species:ncbi:9606">patients</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
The neuropeptides BN/GRP, CGRP, NPY, SP, and VIP were detected in synovial fluid in 70 to 95% of the patients (Table 1). A statistically significant difference between the two groups, patients with early and those with long-standing RA, was found only for BN/GRP (P < 0.05) (Fig. 1b). SP and BN/GRP values in healthy controls were significantly lower than in the two disease groups (P < 0.001) (Fig. 1b,c). The values found for control patients are shown in Table 1.
###end p 26
###begin title 27
sTNFR1 in serum
###end title 27
###begin p 28
###xml 62 63 62 63 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 69 71 69 71 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2a</xref>
###xml 145 147 145 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Soluble TNFR1 was measurable in sera from all subjects (Table 2; Fig 2a.) Differences between the two disease groups were close to significance (P < 0.09).
###end p 28
###begin title 29
Neuropeptides in serum
###end title 29
###begin p 30
###xml 132 133 132 133 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 283 285 283 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 299 301 299 301 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F2">2b</xref>
###xml 315 317 315 317 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 383 384 383 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 116 124 <span type="species:ncbi:9606">patients</span>
###xml 200 208 <span type="species:ncbi:9606">patients</span>
###xml 355 363 <span type="species:ncbi:9606">patients</span>
The concentrations of the neuropeptides BN/GRP, CGRP, NPY, SP, and VIP in sera were measurable in 85 to 100% of the patients (Table 2). Statistically significant differences between the two groups of patients, those with early and those with long-standing RA, were found for BN/GRP (P < 0.05) (Fig. 2b) and for SP (P < 0.05). The values found for control patients are shown in Table 2.
###end p 30
###begin title 31
Correlations between cytokines and neuropeptides in synovial fluid
###end title 31
###begin p 32
###xml 228 229 228 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F3">3</xref>
###xml 326 328 322 324 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 336 338 332 334 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Spearman rank correlations between the concentrations of cytokines and those of the five neuropeptides were calculated. There was a correlation between IL-6 and BN/GRP-like peptides in long-standing RA but not in early RA (Fig. 3). There was also a correlation between TNF-alpha and BN/GRP-like peptides in long-standing RA (rs = 0.40; P < 0.05), but not in the early RA group.
###end p 32
###begin p 33
###xml 174 175 174 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 271 272 271 272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Factor analysis performed on the long-standing RA group yielded four factors with eigenvalues >1, explaining 78% of the total variation between the measured variables (Table 3). SP, BN/GRP, and IL-6 grouped together, with the larger loadings on BN/GRP and on IL-6 (Table 3) in the group with long-standing RA. There was also an interrelation between SP, TNF-alpha, and MCP-1. None of the other three neuropeptides (NPY, CGRP, and VIP) showed any correlation with any of the cytokines. The ESR grouped together with three neuropeptides (BN/GRP, SP, and CGRP), with the largest loadings on SP and on the ESR.
###end p 33
###begin title 34
Correlations between sTNFR1 and neuropeptides in serum
###end title 34
###begin p 35
###xml 48 50 48 50 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 58 60 58 60 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 204 205 204 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="fig" rid="F4">4</xref>
Strong correlations on the Spearman rank test (rs = 0.61; P < 0.05) between concentrations of BN/GRP and those of sTNFR1 were found in the group with long-standing RA, but not in that with early RA (Fig. 4). No correlations were found between sTNFR1 concentrations and the concentrations of the other neuropeptides.
###end p 35
###begin p 36
###xml 180 181 180 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
Factor analysis performed on the group with long-standing RA yielded three factors with eigenvalues >1, explaining 81% of the total variation between the measured variables (Table 4). It can be seen here that BN/GRP grouped together with sTNFR1 and CGRP. None of the other neuropeptides showed any correlation with sTNFR1. It was also seen that the ESR grouped together with sTNFR1.
###end p 36
###begin title 37
Correlations between the neuropeptides in synovial fluid
###end title 37
###begin p 38
###xml 112 113 112 113 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 113 115 113 115 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 123 125 123 125 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 140 142 140 142 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 150 152 150 152 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 171 172 171 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 172 174 172 174 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 182 184 182 184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 224 225 224 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 225 227 225 227 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 234 236 234 236 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Spearman rank correlations showed that the concentrations of NPY in synovial fluid correlated with those of SP (rs = 0.41; P < 0.05), VIP (rs = 0.69; P < 0.01), and CGRP (rs = 0.52; P < 0.05). VIP also correlated with CGRP (rs = 0.7; P < 0.001).
###end p 38
###begin p 39
###xml 123 124 123 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Factor analysis showed that all five neuropeptides grouped together, with the larger loadings on VIP, CGRP, and NPY (Table 3).
###end p 39
###begin title 40
Correlations between the neuropeptides in serum
###end title 40
###begin p 41
###xml 110 112 110 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 120 122 120 122 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 136 138 136 138 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 146 148 146 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 165 167 165 167 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 175 177 175 177 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 243 245 243 245 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 253 255 253 255 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 272 274 272 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 283 285 283 285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
###xml 368 370 368 370 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 378 380 378 380 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r </italic>
Spearman's rank correlations showed that the concentrations of BN/GRP in serum correlated with those of CGRP (P < 0.01; r = 0.70), VIP (P < 0.05; r = 0.51), and SP (P < 0.01; r = 0.58). Concentrations of SP also correlated with those of CGRP (P < 0.01; r = 0.54) and VIP (P < 0.001; r = 0.83). Furthermore, the concentrations of VIP correlated with the those of CGRP (P < 0.01; r = 0.54).
###end p 41
###begin p 42
###xml 78 79 78 79 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
All the neuropeptides grouped together in the factor analysis on serum (Table 4).
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 1069 1071 1065 1067 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 1072 1074 1068 1070 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 111 119 <span type="species:ncbi:9606">patients</span>
###xml 821 829 <span type="species:ncbi:9606">patients</span>
In the present study, the relations between various neuropeptides and cytokines in joint fluid and serum of RA patients were examined. Although there were, to a certain extent, correlations between the various neuropeptides examined, a major finding was that BN/GRP and SP were the neuropeptides that correlated most clearly with the cytokines, with BN/GRP showing the highest degree of correlation. We stress that the occurrence of possible relations were sought extensively, using both Spearman correlation analyses and factor analysis. We also observed that the concentrations of BN/GRP and SP in synovial fluid grouped together with the ESR. These observations suggest that BN/GRP and SP are connected to inflammation in the joint. Comparison with the values obtained from healthy controls showed clearly that in the patients in the long-standing RA group, there were increases in concentrations of the cytokines examined, as well as in concentrations of SP and BN/GRP. It is well established that TNF-alpha is undetectable in synovial fluid from healthy controls [23,27].
###end p 44
###begin p 45
###xml 108 110 108 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B54">54</xref>
###xml 220 222 216 218 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 355 357 351 353 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 613 615 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 616 618 600 602 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
###xml 884 886 861 863 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 197 202 <span type="species:ncbi:9606">human</span>
###xml 874 882 <span type="species:ncbi:9606">patients</span>
CGRP, NPY, SP, and VIP have all been shown to affect cytokine production/release from various immune cells [39,40,44,54]. For example, SP can modulate the release of IL-1, IL-6, and TNF-alpha from human blood monocytes [39]. The stimulatory effect of SP on these proinflammatory cytokines was due to an augmented secretion from the immunocompetent cells [41]. SP and VIP have opposite roles concerning the regulation of TNF-alpha production, VIP inhibiting the production of TNF-alpha from, for example, microglia, and SP increasing the TNF-alpha production from mast cells and other types of inflammatory cells [40,41]. The impact of neuropeptides on cytokine production and release in RA is not well known. However, in a recent study it was shown that CGRP, NPY, SP and VIP could affect the IL-1beta, TNF-alpha, and IL-6 production by peripheral whole blood cells from RA patients [44]. In the present study, we searched for possible correlations of TNFalpha, IL-6, and MCP-1 with all neuropeptides included in the analyses of the synovial fluid, but no correlations were found concerning VIP, NPY, or CGRP. The situation was the same for correlation matrices between sTNFR1 and these three neuropeptides in serum.
###end p 45
###begin p 46
###xml 88 90 88 90 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 91 93 91 93 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 290 292 290 292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B33">33</xref>
###xml 293 295 293 295 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B55">55</xref>
###xml 441 443 441 443 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B56">56</xref>
###xml 998 1000 990 992 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B57">57</xref>
###xml 78 86 <span type="species:ncbi:9606">patients</span>
###xml 795 803 <span type="species:ncbi:9606">patients</span>
Because IL-6 was found in elevated concentrations in the synovial fluid of RA patients [33,55], the importance of this cytokine in RA and other diseases has been thoroughly investigated. It has been shown that IL-6 regulates acute-phase proteins such as C-reactive protein and haptoglobin [33,55]. Furthermore, a humanised anti-IL-6 receptor antibody has been found to inhibit IL-6 significantly and to improve the signs and symptoms of RA [56]. In the analysis of synovial fluid in the present study, we found that BN/GRP and SP grouped together with IL-6, with the strongest loadings on BN/GRP and on IL-6. This is one of the major findings leading to the interpretation that these two neuropeptides correlate more closely than the others with disease activity in RA. In the synovial fluid of patients with long-standing RA, there was also a correlation between BN/GRP and TNF-alpha. As it is well known that TNF-alpha and other cytokines may occur in insufficient concentrations in serum (e.g. [57]), we analysed sTNFR1 in serum and found that the receptor concentrations correlated with concentrations of BN/GRP on the Spearman's rank analysis and that they grouped together on the factor analysis.
###end p 46
###begin p 47
###xml 157 159 157 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B58">58</xref>
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B59">59</xref>
###xml 276 278 276 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B60">60</xref>
###xml 410 412 410 412 <sub xmlns:xlink="http://www.w3.org/1999/xlink">2 </sub>
###xml 457 458 457 458 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 570 572 570 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 770 772 770 772 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
It has long been discussed as to whether SP is clinically significant in RA, and accordingly whether SP-receptor antagonists block joint inflammation (e.g. [58,59]). In early studies, it was shown that intra-articular injections of SP increased the severity of the arthritis [60]. This substance was also early shown to facilitate the production and release of proinflammatory mediators such as prostaglandin E2 and destructive enzymes such as collagenase [6]. In more recent studies, intra-articular injection of SP was found to lead to endothelial-cell proliferation [61]. The overall role of SP in RA has recently been extensively discussed and it was concluded that the therapeutic potential of SP receptor (neurokinin-1 receptor) antagonists should not be ignored [45].
###end p 47
###begin p 48
###xml 51 53 51 53 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B62">62</xref>
###xml 75 77 75 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B63">63</xref>
###xml 90 92 90 92 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B64">64</xref>
###xml 323 325 323 325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B65">65</xref>
###xml 326 328 326 328 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B66">66</xref>
###xml 510 512 510 512 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B67">67</xref>
###xml 513 515 513 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B69">69</xref>
###xml 679 680 679 680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 681 683 681 683 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 684 686 684 686 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 687 689 687 689 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 690 692 690 692 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B70">70</xref>
###xml 693 695 693 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B72">72</xref>
###xml 664 672 <span type="species:ncbi:9606">patients</span>
###xml 826 834 <span type="species:ncbi:9606">patients</span>
###xml 930 938 <span type="species:ncbi:9606">patients</span>
SP is present in the nerve fibres of the synovium [62]. However, both up- [63] and down- [64] regulation of SP expression has been noted for arthritic joints. In accord with these observations, up- and down-regulations of neuropeptide expressions occur in relation to the activity of inflammatory disease in other tissues [65,66]. A reason for decreased magnitude of SP in the nerve fibres of joint capsules may be the occurrence of a local release of SP, leading to a depletion of SP-containing nerve fibres [67-69]. There are also diverging observations concerning the occurrence of increases or decreases of SP concentrations in the synovial fluid of arthritic patients (cf. [7,10,11,16,70-72]). Taking into consideration that neuropeptide and cytokine concentrations may vary depending upon the stage of arthritis for the patients examined and that differences in actual neuropeptide concentrations in serum between different patients should be interpreted with caution, an advantage of the present study is that it focuses on intraindividual comparisons of neuropeptide and cytokine concentrations.
###end p 48
###begin p 49
###xml 244 246 244 246 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B73">73</xref>
###xml 508 510 508 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B74">74</xref>
###xml 511 513 511 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B76">76</xref>
###xml 597 599 597 599 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B77">77</xref>
###xml 653 655 653 655 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B78">78</xref>
###xml 787 789 787 789 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B79">79</xref>
###xml 884 886 884 886 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B80">80</xref>
###xml 1215 1217 1215 1217 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B81">81</xref>
###xml 1325 1327 1325 1327 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B82">82</xref>
###xml 1398 1400 1398 1400 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B83">83</xref>
###xml 1704 1706 1704 1706 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B84">84</xref>
###xml 1792 1794 1792 1794 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B85">85</xref>
###xml 224 229 <span type="species:ncbi:9606">human</span>
###xml 971 979 <span type="species:ncbi:9606">patients</span>
It is not clear whether BN/GRP-like peptides are present in joint innervation, or how the release of the peptides into the synovial fluid occurs. An interesting observation is that BN/GRP-like peptides have been detected in human chondrocytes [73]. In any case, BN/GRP-like peptides are well known to have trophic and growth-promoting effects in various parts of the body. Thus, these peptides have paracrine and autocrine trophic effects in certain cancers, such as small-cell lung cancer and colon cancer [74-76], and are likely to have trophic effects on the salivary glands after irradiation [77] and to promote proliferation of fetal chondrocytes [78]. Furthermore, GRP receptors have morphogenetic properties for colon cancer cells, these being mediated via focal adhesion kinase [79]. The expression of BN/GRP-like peptides in the spinal cord is influenced by glucocorticoids [80], which may be of interest for the understanding of the effects of treatments of RA patients, many of whom are treated with glucocorticoids. Concerning inflammation, it has been shown that BN/GRP-like peptides ameliorate burn-induced intestinal inflammation by preventing the sequestration of neutrophils in the injured tissue [81] and that these peptides presumably are mediators of inflammatory reactions during pulmonary inflammation [82]. Furthermore, BN ameliorates colonic damage in experimental colitis [83], which suggests that the peptide may be involved in restoring intestinal damage in inflammatory bowel disease. Treatment with BN/GRP has also been found to have antiulcerogenic and anti-inflammatory actions, related to effects on chronic gastric ulcers and burn-induced and colitis-induced gut injury [84]. Furthermore, topical use of GRP has been found to promote cutaneous wound healing [85].
###end p 49
###begin p 50
###xml 111 113 111 113 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 114 116 114 116 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 117 119 117 119 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 188 196 188 196 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vivo </italic>
###xml 233 235 233 235 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 236 238 236 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B86">86</xref>
###xml 284 293 284 293 <italic xmlns:xlink="http://www.w3.org/1999/xlink">in vitro </italic>
###xml 524 526 516 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B51">51</xref>
###xml 577 579 569 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B50">50</xref>
###xml 1036 1038 1028 1030 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B87">87</xref>
###xml 1071 1073 1063 1065 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B88">88</xref>
###xml 1354 1356 1346 1348 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B89">89</xref>
###xml 1640 1642 1632 1634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B45">45</xref>
###xml 1846 1848 1838 1840 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B90">90</xref>
###xml 227 231 <span type="species:ncbi:10090">mice</span>
###xml 272 277 <span type="species:ncbi:9606">human</span>
###xml 436 444 <span type="species:ncbi:9606">patients</span>
The present study is relevant because neuropeptides have been suggested to be efficacious antiarthritic drugs [17,50,51]. Thus, VIP was shown to be effective as an anti-inflammatory agent in vivo for collagen-induced arthritic mice [17,86]. Furthermore, a recent study on human cells in vitro showed that VIP can down-regulate the expression and synthesis of chemokines in synovial tissue cells and fibroblast-like synoviocytes from RA patients and that VIP inhibits the production of TNF-alpha after TNF-alpha stimulation [51]. The results obtained by Foey and collaborators [50] show that the studied neuropeptide (VIP) is not on its own a useful therapeutic agent in the treatment of RA but may be useful in combination with phosphodiesterase inhibitor. In line with this idea, it has frequently been suggested that various types of combination treatments might be effective in diseases such as RA. It was initially suggested that a combination therapy targeting two cytokines instead of one would be the treatment of choice for RA [87] and other autoimmune diseases [88]. However, in a recent clinical trial it was observed that a combination therapy with a recombinant IL-1 receptor antagonist and polyethylene-glycol-conjugated sTNFRI (etanercept) did not result in an improvement of the clinical factors of RA in comparison with etanercept alone [89]. Alternative combination treatments might in the future include treatments targeting cytokine and neuropeptide. In line with this idea, it was recently suggested that SP-receptor (neurokinin-1 receptor) antagonists might be useful in combination with pre-existing treatments in RA [45]. In a recent study, a combination of common chemotherapy and immunotherapy targeting BN/GRP-receptor with a synthetic BN/GRP antagonist was found to enhance the killing of small-cell lung cancer cells [90].
###end p 50
###begin p 51
###xml 232 234 232 234 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B44">44</xref>
###xml 634 636 634 636 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B91">91</xref>
###xml 677 679 677 679 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B61">61</xref>
###xml 214 222 <span type="species:ncbi:9606">patients</span>
As discussed above, there is indeed evidence showing that neuropeptides can modify the secretion of proinflammatory cytokines from immunocompetent cells. That includes the situation for peripheral blood cells from patients with RA [44]. As seen in the present study, BN/GRP and SP are the peptides that show correlations with the inflammatory cytokines in RA. Thus, we tentatively suggest that the increased concentrations of BN/GRP and SP may stimulate cytokine production from immunocompetent cells in RA. The findings that neurokinin-1 receptor is not only detectable on immunocompetent cells, but also on rheumatoid synoviocytes [91] and on endothelial cells in synovitis [61], strengthen the suggestion that SP plays an important role in the rheumatoid joint. In future studies, it would therefore be of interest to investigate whether BN/GRP and its receptor are active during the rheumatic process, and whether treatments interfering with the effects of BN/GRP or SP or both, possibly in parallel with medications affecting cytokine effects, are of value in RA.
###end p 51
###begin title 52
Conclusion
###end title 52
###begin p 53
###xml 85 92 <span type="species:ncbi:9606">patient</span>
The neuropeptides that showed correlations with the proinflammatory cytokines in the patient material examined were BN/GRP and SP, particularly BN/GRP. The observations give new insight into further studies of neuropeptide/cytokine interrelations in RA.
###end p 53
###begin title 54
Abbreviations
###end title 54
###begin p 55
BN/GRP = bombesin/gastrin-releasing peptide; CGRP = calcitonin-gene-related peptide; ELISA = enzyme-linked immunosorbent assay; ESR = erythrocyte sedimentation rate; GRP = gastrin-releasing peptide; IL = interleukin; MCP-1 = monocyte chemoattractant protein-1; NPY = neuropeptide Y; RA = rheumatoid arthritis; RIA = radio-immunoassay; SP = substance P; sTNFR1 = soluble TNF receptor 1; Th = T helper (cells); TNF = tumour necrosis factor; VIP = vasoactive intestinal peptide.
###end p 55
###begin title 56
Competing interests
###end title 56
###begin p 57
The author(s) declare that they have no competing interests.
###end p 57
###begin title 58
Authors' contributions
###end title 58
###begin p 59
OG participated in the design of the study, carried out the immunoassays, and performed the statistical analysis. SF participated in the design, coordinated the study, and took part in the statistical analysis. OG and SF drafted the manuscript. SRD was responsible for collection of the samples, participated in the statistical analysis, contributed to the coordination of the study, and took part in discussions concerning the manuscript. All authors read and approved the final manuscript.
###end p 59
###begin title 60
Acknowledgements
###end title 60
###begin p 61
The authors are grateful to Ms Ulla Hedlund and Ms Lena Jonsson for excellent technical services. We also thank Ms Solveig Jonsson-Wallberg for contributing to the collection of the samples. We are also grateful to Mr Hans Stenlund for help with the statistical analysis. This study was supported by the Faculty of Medicine, Umea University.
###end p 61
###begin article-title 62
###xml 62 68 <span type="species:ncbi:10090">murine</span>
Upregulation of neuropeptides and neuropeptide receptors in a murine model of immune inflammation in lung parenchyma
###end article-title 62
###begin article-title 63
Several mediators appear to interact in neurogenic inflammation
###end article-title 63
###begin article-title 64
Peptides and neurogenic inflammation
###end article-title 64
###begin article-title 65
###xml 43 48 <span type="species:ncbi:9606">human</span>
Eosinophils within the healthy or inflamed human intestine produce substance P and vasoactive intestinal peptide
###end article-title 65
###begin article-title 66
The effects of tachykinins on inflammatory and immune cells
###end article-title 66
###begin article-title 67
Substance P activation of rheumatoid synoviocytes: neural pathway in pathogenesis of arthritis
###end article-title 67
###begin article-title 68
Neuropeptides and steroid hormones in arthritis
###end article-title 68
###begin article-title 69
###xml 114 122 <span type="species:ncbi:9606">patients</span>
Co-variation of neuropeptide Y, calcitonin gene-related peptide, substance P and neurokinin A in joint fluid from patients with temporomandibular joint arthritis
###end article-title 69
###begin article-title 70
Neuropeptides in temporomandibular joints with rheumatoid arthritis: a clinical study
###end article-title 70
###begin article-title 71
###xml 116 124 <span type="species:ncbi:9606">patients</span>
Calcitonin gene-related peptide II, substance P and vasoactive intestinal peptide in plasma and synovial fluid from patients with inflammatory joint disease
###end article-title 71
###begin article-title 72
###xml 37 42 <span type="species:ncbi:9606">human</span>
Increased content of bombesin/GRP in human synovial fluid in early arthritis: different pattern compared with substance P
###end article-title 72
###begin article-title 73
###xml 74 79 <span type="species:ncbi:9606">human</span>
###xml 107 112 <span type="species:ncbi:9606">human</span>
Molecular biology of bombesin-like peptides. Comparison of cDNAs encoding human gastrin-releasing peptide, human neuromedin B, and amphibian ranatensin
###end article-title 73
###begin article-title 74
Isolation and structure of bombesin and alytesin, 2 analogous active peptides from the skin of the European amphibians Bombina and Alytes
###end article-title 74
###begin article-title 75
Bombesin: receptor distribution in brain and effects on nociception and locomotor activity
###end article-title 75
###begin article-title 76
Centrally applied bombesin increases nerve activity of both sympathetic and adrenal branch of the splanchnic nerves
###end article-title 76
###begin article-title 77
###xml 168 176 <span type="species:ncbi:9606">patients</span>
Concentration of substance P, neurokinin A, calcitonin gene-related peptide, neuropeptide Y and vasoactive intestinal polypeptide in synovial fluid from knee joints in patients suffering from rheumatoid arthritis
###end article-title 77
###begin article-title 78
Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease
###end article-title 78
###begin article-title 79
###xml 153 161 <span type="species:ncbi:9606">patients</span>
Evidence for neural regulation of inflammatory synovial cell functions by secreting calcitonin gene-related peptide and vasoactive intestinal peptide in patients with rheumatoid arthritis
###end article-title 79
###begin article-title 80
VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells
###end article-title 80
###begin article-title 81
###xml 131 137 <span type="species:ncbi:10090">murine</span>
Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide modulate endotoxin-induced IL-6 production by murine peritoneal macrophages
###end article-title 81
###begin article-title 82
Inhibition of endotoxin-induced macrophage chemokine production by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide in vitro and in vivo
###end article-title 82
###begin article-title 83
Vasoactive intestinal peptide inhibits interleukin (IL)-2 and IL-4 production through different molecular mechanisms in T cells activated via the T cell receptor/CD3 complex
###end article-title 83
###begin article-title 84
TNF alpha - a pivotal role in rheumatoid arthritis?
###end article-title 84
###begin article-title 85
Regulation of cytokines, cytokine inhibitors, and acute-phase proteins following anti-TNF-alpha therapy in rheumatoid arthritis
###end article-title 85
###begin article-title 86
###xml 113 121 <span type="species:ncbi:9606">patients</span>
Dynamic changes in cytokine levels in serum and synovial fluid following filtration leukocytapheresis therapy in patients with rheumatoid arthritis
###end article-title 86
###begin article-title 87
Synovial fluid levels of tumor necrosis factor alpha and oncostatin M correlate with levels of markers of the degradation of crosslinked collagen and cartilage aggrecan in rheumatoid arthritis but not in osteoarthritis
###end article-title 87
###begin article-title 88
Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum
###end article-title 88
###begin article-title 89
###xml 68 76 <span type="species:ncbi:9606">patients</span>
Detection of cytokine producing cells in the synovial membrane from patients with rheumatoid arthritis
###end article-title 89
###begin article-title 90
###xml 65 69 <span type="species:ncbi:10090">mice</span>
Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA)
###end article-title 90
###begin article-title 91
###xml 47 55 <span type="species:ncbi:9606">patients</span>
Elevated TNF receptor plasma concentrations in patients with rheumatoid arthritis
###end article-title 91
###begin article-title 92
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases
###end article-title 92
###begin article-title 93
###xml 89 97 <span type="species:ncbi:9606">patients</span>
Circulating tumour necrosis factor alpha and soluble tumour necrosis factor receptors in patients with different patterns of rheumatoid synovitis
###end article-title 93
###begin article-title 94
###xml 45 53 <span type="species:ncbi:9606">patients</span>
Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides
###end article-title 94
###begin article-title 95
###xml 44 49 <span type="species:ncbi:9606">human</span>
###xml 118 123 <span type="species:ncbi:9606">human</span>
Purification and amino acid analysis of two human monocyte chemoattractants produced by phytohemagglutinin-stimulated human blood mononuclear leukocytes
###end article-title 95
###begin article-title 96
###xml 44 49 <span type="species:ncbi:9606">human</span>
Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants
###end article-title 96
###begin article-title 97
###xml 94 99 <span type="species:ncbi:10090">mouse</span>
An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model
###end article-title 97
###begin article-title 98
Monocyte chemoattractant protein-1 (MCP-1) in inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium
###end article-title 98
###begin article-title 99
Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis
###end article-title 99
###begin article-title 100
###xml 67 72 <span type="species:ncbi:9606">human</span>
Effect of neuropeptides on production of inflammatory cytokines by human monocytes
###end article-title 100
###begin article-title 101
Vasoactive intestinal peptide and pituitary adenylyl cyclase-activating polypeptide inhibit tumor necrosis factor-alpha production in injured spinal cord and in activated microglia via a cAMP-dependent pathway
###end article-title 101
###begin article-title 102
###xml 102 107 <span type="species:ncbi:9606">human</span>
Substance P and calcitonin gene-related peptide increase IL-1 beta, IL-6 and TNF alpha secretion from human peripheral blood mononuclear cells
###end article-title 102
###begin article-title 103
Protective effect of sensory denervation in inflammatory arthritis evidence of regulatory neuroimmune pathways in the arthritic joint
###end article-title 103
###begin article-title 104
###xml 35 40 <span type="species:ncbi:9606">human</span>
Neuropeptides and interleukin-6 in human joint inflammation relationship between intraarticular substance P and interleukin-6 concentrations
###end article-title 104
###begin article-title 105
###xml 262 270 <span type="species:ncbi:9606">patients</span>
Effect of calcitonin gene-related peptide, neuropeptide Y, substance P, and vasoactive intestinal peptide on interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha production by peripheral whole blood cells from rheumatoid arthritis and osteoarthritis patients
###end article-title 105
###begin article-title 106
A role for substance P in arthritis?
###end article-title 106
###begin article-title 107
Distinct mechanism for antidepressant activity by blockade of central substance P receptors
###end article-title 107
###begin article-title 108
The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials
###end article-title 108
###begin article-title 109
###xml 71 75 <span type="species:ncbi:10090">mice</span>
Inhibition of inflammation and hyperalgesia in NK-1 receptor knock-out mice
###end article-title 109
###begin article-title 110
###xml 104 108 <span type="species:ncbi:10116">rats</span>
NK-1 antagonist reduces colonic inflammation and oxidative stress in dextran sulfate-induced colitis in rats
###end article-title 110
###begin article-title 111
Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis
###end article-title 111
###begin article-title 112
Vasoactive intestinal peptide modulates proinflammatory mediator synthesis in osteoarthritic and rheumatoid synovial cells
###end article-title 112
###begin article-title 113
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
###end article-title 113
###begin article-title 114
Differential effects of gastrin-releasing peptide, neuropeptide Y, somatostatin and vasoactive intestinal peptide on interleukin-1 beta, interleukin-6 and tumor necrosis factor-alpha production by whole blood cells from healthy young and old subjects
###end article-title 114
###begin article-title 115
###xml 52 60 <span type="species:ncbi:9606">patients</span>
Interleukin-6 (IL-6) in synovial fluid and serum of patients with rheumatic diseases
###end article-title 115
###begin article-title 116
Treatment of rheumatoid arthritis with humanized anti-interleukin-6 receptor antibody: a multicenter, double-blind, placebo-controlled trial
###end article-title 116
###begin article-title 117
###xml 63 68 <span type="species:ncbi:9606">human</span>
Cytokine measurements and interpretation of cytokine assays in human disease
###end article-title 117
###begin article-title 118
###xml 53 56 <span type="species:ncbi:10116">rat</span>
Mediators of substance P-induced inflammation in the rat knee joint
###end article-title 118
###begin article-title 119
###xml 54 57 <span type="species:ncbi:10116">rat</span>
Inhibition of carrageenan induced inflammation in the rat knee joint by substance P antagonist
###end article-title 119
###begin article-title 120
Intraneuronal substance P contributes to the severity of experimental arthritis
###end article-title 120
###begin article-title 121
Combined effect of bradykinin B2 and neurokinin-1 receptor activation on endothelial cell proliferation in acute synovitis
###end article-title 121
###begin article-title 122
###xml 94 97 <span type="species:ncbi:10116">rat</span>
Distribution of neuropeptide-containing nerve fibers in the synovium and adjacent bone of the rat knee joint
###end article-title 122
###begin article-title 123
###xml 107 111 <span type="species:ncbi:10116">rats</span>
Changes in preprotachykinin mRNA expression and substance P levels in dorsal root ganglia of monoarthritic rats: comparison with changes in synovial substance P levels
###end article-title 123
###begin article-title 124
###xml 101 105 <span type="species:ncbi:10116">rats</span>
Relationship between neuropeptide immunoreactive nerves and inflammatory cells in adjuvant arthritic rats
###end article-title 124
###begin article-title 125
Substance P containing nerve fibers in rectal mucosa of ulcerative colitis
###end article-title 125
###begin article-title 126
Colonic vasoactive intestinal polypeptide (VIP) in ulcerative colitis - a radioimmunoassay and immunohistochemical study
###end article-title 126
###begin article-title 127
###xml 29 37 <span type="species:ncbi:9606">patients</span>
Neuropeptides in synovium of patients with rheumatoid arthritis and osteoarthritis
###end article-title 127
###begin article-title 128
###xml 157 165 <span type="species:ncbi:9606">patients</span>
Substance P-, calcitonin gene-related peptide- and C-flanking peptide of neuropeptide Y-immunoreactive fibres are present in normal synovium but depleted in patients with rheumatoid arthritis
###end article-title 128
###begin article-title 129
###xml 29 34 <span type="species:ncbi:9606">human</span>
Peptide containing nerves in human synovium: immunohistochemical evidence for decreased innervation in rheumatoid arthritis
###end article-title 129
###begin article-title 130
###xml 66 74 <span type="species:ncbi:9606">patients</span>
Neutral endopeptidase (3.4.24.11) in plasma and synovial fluid of patients with rheumatoid arthritis. A marker of disease activity or a regulator of pain and inflammation?
###end article-title 130
###begin article-title 131
High levels of substance P in rheumatoid arthritis synovial fluid. Lack of substance P production by synoviocytes in vitro
###end article-title 131
###begin article-title 132
Substance P and arthritis: analysis of plasma and synovial fluid levels
###end article-title 132
###begin article-title 133
###xml 18 23 <span type="species:ncbi:9606">human</span>
Neuropeptides and human osteoarthritis
###end article-title 133
###begin article-title 134
Selective stimulation of small cell lung cancer clonal growth by bombesin and gastrin-releasing peptide
###end article-title 134
###begin article-title 135
###xml 67 72 <span type="species:ncbi:9606">human</span>
Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer
###end article-title 135
###begin article-title 136
###xml 90 95 <span type="species:ncbi:9606">human</span>
Bombesin stimulates adhesion, spreading, lamellipodia formation, and proliferation in the human colon carcinoma Isreco1 cell line
###end article-title 136
###begin article-title 137
Bombesin-like peptide is present in duct cells in salivary glands: studies on normal and irradiated animals
###end article-title 137
###begin article-title 138
Mitogenic action of gastrin-releasing polypeptide on isolated epiphyseal growth plate chondrocytes from the ovine fetus
###end article-title 138
###begin article-title 139
Expression of GRP and its receptor in well-differentiated colon cancer cells correlates with the presence of focal adhesion kinase phosphorylated at tyrosines 397 and 407
###end article-title 139
###begin article-title 140
###xml 78 81 <span type="species:ncbi:10116">rat</span>
Dexamethasone treatment after adrenalectomy increases bombesin content in the rat spinal cord [abstract]
###end article-title 140
###begin article-title 141
###xml 56 59 <span type="species:ncbi:10116">rat</span>
Bombesin improves burn-induced intestinal injury in the rat
###end article-title 141
###begin article-title 142
Bombesin-like peptides in alveolar macrophage: increased release in pulmonary inflammation and fibrosis
###end article-title 142
###begin article-title 143
Bombesin ameliorates colonic damage in experimental colitis
###end article-title 143
###begin article-title 144
Bombesin-like peptides: candidates as diagnostic and therapeutic tools
###end article-title 144
###begin article-title 145
Gastrin-releasing peptide, a bombesin-like neuropeptide, promotes cutaneous wound healing
###end article-title 145
###begin article-title 146
Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis
###end article-title 146
###begin article-title 147
Cytokines and cytokine-directed intervention in experimental arthritis
###end article-title 147
###begin article-title 148
Immune regulation in multiple sclerosis: Cytokines and metalloproteinases
###end article-title 148
###begin article-title 149
###xml 69 77 <span type="species:ncbi:9606">patients</span>
Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate
###end article-title 149
###begin article-title 150
Bombesin/gastrin-releasing peptide receptor: a potential target for antibody-mediated therapy of small cell lung cancer
###end article-title 150
###begin article-title 151
Substance P receptor (NK1) gene expression in synovial tissue in rheumatoid arthritis and osteoarthritis
###end article-title 151
###begin title 152
Figures and Tables
###end title 152
###begin p 153
###xml 106 110 106 110 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 116 120 116 120 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 156 160 156 160 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(c) </bold>
###xml 305 307 305 307 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
Box-whisker plots showing concentrations in synovial fluid for rheumatoid arthritis and healthy controls. (a) IL-6; (b) bombesin/gastrin-releasing peptide; (c) substance P. Boxes show the 25th and 75th percentiles; horizontal lines in boxes show the medians; whiskers show the 10th and 90th percentiles. *P < 0.05.
###end p 153
###begin p 154
###xml 115 119 115 119 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(a) </bold>
###xml 162 166 162 166 <bold xmlns:xlink="http://www.w3.org/1999/xlink">(b) </bold>
###xml 334 336 334 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 58 66 <span type="species:ncbi:9606">patients</span>
Box-whisker plots showing concentrations in serum for the patients with rheumatoid arthritis and healthy controls. (a) Soluble tumour necrosis factor receptor 1; (b) bombesin/gastrin-releasing peptide. Boxes show the 25th and 75th percentiles; horizontal lines in boxes show the medians; whiskers show the 10th and 90th percentiles. *P < 0.05.
###end p 154
###begin p 155
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 148 150 148 150 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 158 160 158 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 222 230 <span type="species:ncbi:9606">patients</span>
Scatter plot, with linear regression line, showing correlation between BN/GRP and IL-6 in synovial fluid. Spearman's rank correlation coefficient (rs = 0.38; P < 0.05) measured, using RIA and ELISA, in synovial fluid from patients with long-standing RA. BN/GRP, bombesin/gastrin-releasing peptide; RA, rheumatoid arthritis.
###end p 155
###begin p 156
###xml 141 143 141 143 <sub xmlns:xlink="http://www.w3.org/1999/xlink">s </sub>
###xml 151 153 151 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 199 207 <span type="species:ncbi:9606">patients</span>
Scatter plot, with linear regression line, showing correlation between BN/GRP and sTNFR1 in serum. Spearman's rank correlation coefficient (rs = 0.61; P < 0.05), measured, using ELISA, in serum from patients with long-standing RA. BN/GRP, bombesin/gastrin-releasing peptide; RA, rheumatoid arthritis; sTNFR1, soluble TNF receptor 1.
###end p 156
###begin p 157
Cytokine and neuropeptide concentrations in synovial fluid
###end p 157
###begin p 158
###xml 163 164 163 164 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 166 167 166 167 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 170 172 170 172 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 237 238 237 238 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 238 240 238 240 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 245 246 245 246 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 246 248 246 248 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 253 254 253 254 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 254 256 254 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 262 263 262 263 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 263 265 263 265 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 271 272 271 272 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 272 274 272 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 280 281 280 281 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
###xml 281 283 281 283 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 288 289 288 289 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g</sup>
###xml 88 96 <span type="species:ncbi:9606">patients</span>
Concentrations were measured by ELISA and RIA in synovial fluid from the knee joints of patients with RA and in healthy control subjects. Values are medians (and Q1-Q3). P relates to long-standing RA versus early RA (Mann-Whitney test). an = 7; bn = 6; cn = 28; dn = 23; en = 25; fn = 2; gn = 10. BN/GRP, bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; MCP-1, monocyte chemoattractant protein-1; nd, not detectable; nm, not measured; NPY, neuropeptide Y; ns, not significant; RA, rheumatoid arthritis; SP, substance P; TNF, tumour necrosis factor; VIP, vasoactive intestinal peptide.
###end p 158
###begin p 159
Concentrations of sTNFR1 and neuropeptides in serum
###end p 159
###begin p 160
###xml 67 68 67 68 <sub xmlns:xlink="http://www.w3.org/1999/xlink">1</sub>
###xml 70 71 70 71 <sub xmlns:xlink="http://www.w3.org/1999/xlink">3</sub>
###xml 97 99 97 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P </italic>
###xml 144 145 144 145 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 145 147 145 147 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 152 153 152 153 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 153 155 153 155 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 161 162 161 162 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 162 164 162 164 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 170 171 170 171 <sup xmlns:xlink="http://www.w3.org/1999/xlink">d</sup>
###xml 235 236 235 236 <sup xmlns:xlink="http://www.w3.org/1999/xlink">e</sup>
###xml 236 238 236 238 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 243 244 243 244 <sup xmlns:xlink="http://www.w3.org/1999/xlink">f</sup>
###xml 244 246 244 246 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
###xml 251 252 251 252 <sup xmlns:xlink="http://www.w3.org/1999/xlink">g</sup>
###xml 252 254 252 254 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n </italic>
Concentrations were measured using ELISA. Values are medians (and Q1-Q3). The ESR is also shown. P relates to long-standing RA versus early RA. an = 4; bn = 22; cn = 21; dsTNFR1 value in healthy controls according to the manufacturer; en = 4; fn = 2; gn = 11. BN/GRP, bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; ESR, erythrocyte sedimentation rate; NPY, neuropeptide Y; nm, not measured; ns, not significant; RA, rheumatoid arthritis; SP, substance P; sTNFR1, soluble tumour necrosis factor receptor 1; VIP, vasoactive intestinal peptide.
###end p 160
###begin p 161
Factor analysis on cytokines and neuropeptides in synovial fluid
###end p 161
###begin p 162
###xml 87 95 <span type="species:ncbi:9606">patients</span>
Principal-component analysis for cytokines and neuropeptides in synovial fluid from 23 patients with long-standing RA, and for the ESR. BN/GRP, bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; ESR, erythrocyte sedimentation rate; MCP, monocyte chemoattractant protein-1; NPY, neuropeptide Y; RA, rheumatoid arthritis; SP, substance P; TNF, tumour necrosis factor; VIP, vasoactive intestinal peptide.
###end p 162
###begin p 163
Factor analysis on sTNFR1 and neuropeptides in serum
###end p 163
###begin p 164
###xml 80 88 <span type="species:ncbi:9606">patients</span>
Principal-component analysis for sTNFR1 and five neuropeptides in serum from 21 patients with long-standing RA, and for the ESR. BN/GRP, bombesin/gastrin-releasing peptide; CGRP, calcitonin-gene-related peptide; ESR, erythrocyte sedimentation rate; NPY, neuropeptide Y; RA, rheumatoid arthritis; SP, substance P; sTNFR1, soluble tumour necrosis factor receptor 1; VIP, vasoactive intestinal peptide.
###end p 164

